Table 4 The impact of PD guideline awareness on drug selection strategy under specific circumstances
Items | Haven’t read the PD guideline(s) (n=97) | Have read the PD guideline(s) (n=392) | P value |
|---|---|---|---|
Age < 65 years without cognitive impairment | |||
Levodopa | 44(45.4%) | 120(30.6%) | 0.006 |
Dopamine agonists | 25(25.8%) | 185(47.2%) | 0.000 |
MAO-B inhibitors | 7(7.2%) | 55(14.0%) | 0.071 |
Age > 65 years or with cognitive impairment | |||
Levodopa | 58(59.8%) | 219(55.9%) | 0.485 |
Dopamine agonists | 17(17.5%) | 97(24.7%) | 0.132 |
MAO-B inhibitors | 7(7.2%) | 34(8.7%) | 0.643 |
Wearing-off phenomenon | |||
Add levodopa dose | 30(30.9%) | 157(40.1%) | 0.098 |
Switch from standard levodopa to CR levodopa | 31(32.0%) | 205(52.3%) | 0.000 |
Add COMT inhibitors or MAO-B inhibitors | 21(21.6%) | 182(46.4%) | 0.000 |
Add dopamine agonists | 20(20.6%) | 176(44.9%) | 0.000 |
Peak-dose dyskinesia | |||
Reduce levodopa dose, add its frequency | 41(42.3% ) | 177(45.2%) | 0.609 |
Reduce levodopa dose, add dopamine agonists | 31(32.0% ) | 184(46.9%) | 0.008 |
Reduce levodopa dose, add COMT inhibitors | 14(14.4%) | 131(33.4%) | 0.000 |
Add amantadine | 9(9.3%) | 62(15.8%) | 0.102 |
PD with psychosis | |||
Clozapine | 17(17.5%) | 95(24.2%) | 0.159 |
Olanzapine | 42(43.3%) | 182(46.4%) | 0.580 |
Quetiapine | 14(14.4%) | 92(23.5%) | 0.053 |
PD with dementia | |||
Huperzine A | 26(26.8%) | 98(25.0%) | 0.715 |
Donepezil | 51(52.6%) | 212(54.1%) | 0.790 |
Rivastigmine | 8(8.2%) | 74(18.9%) | 0.012 |
Memantine | 26(26.8%) | 159(40.6%) | 0.012 |
PD with depression | |||
Tricyclic antidepressants | 28(28.9%) | 73(18.6%) | 0.026 |
SSRIs | 45(46.4%) | 247(63.0%) | 0.003 |
Pramipexole | 20(20.6%) | 165(42.1%) | 0.000 |
PD with RLS | |||
Levodopa | 19(19.6%) | 104(26.5%) | 0.158 |
Dopamine agonists | 20(20.6%) | 129(32.9%) | 0.019 |
Benzodiazepines | 29(29.9%) | 111(28.3%) | 0.758 |